3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
243
Stomach Neoplasms
23
Breast Neoplasms, Male
16
Neoplasm Metastasis
14
Neoplasms
8
Inflammatory Breast Neoplasms
8
Esophageal Neoplasms
8
Brain Neoplasms
8
Colorectal Neoplasms
6
Adenocarcinoma Of Esophagus
4
Urologic Neoplasms
3
Triple Negative Breast Neoplasms
3
HER2-positive Breast Cancer
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Ductal, Breast
3
Gallbladder Neoplasms
2
Endometrial Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Lobular
2
Carcinoma, Intraductal, Noninfiltrating
2
Biliary Tract Neoplasms
2
Adenocarcinoma
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Solid Cancers
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Patient Preference
1
Patient Compliance
1
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Advanced Unresectable or Metastatic Solid Malignancy
×
Trastuzumab
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts